• [1]

    Ellington A D, Szostak J W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287): 818-822

  • [2]

    Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249(4968): 505-510

  • [3]

    Yik E J, Medina E, Paegel B M, et al. Highly parallelized screening of functionally enhanced XNA aptamers in uniform hydrogel particles. ACS Synth Biol, 2023, 12(7): 2127-2134

  • [4]

    Schofield P, Taylor A I, Rihon J, et al. Characterization of an HNA aptamer suggests a non-canonical G-quadruplex motif. Nucleic Acids Res, 2023, 51(15): 7736-7748

  • [5]

    Narwade M, Shaikh A, Gajbhiye K R, et al. Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery. Biomater Res, 2023, 27(1): 42

  • [6]

    He S, Du Y, Tao H, et al. Advances in aptamer-mediated targeted delivery system for cancer treatment. Int J Biol Macromol, 2023, 238: 124173

  • [7]

    Li Y, Tam W W, Yu Y, et al. The application of aptamer in biomarker discovery. Biomark Res, 2023, 11(1): 70

  • [8]

    Xu G, Zhao J, Yu H, et al. Structural insights into the mechanism of high-affinity binding of ochratoxin A by a DNA aptamer. J Am Chem Soc, 2022, 144(17): 7731-7740

  • [9]

    Xu G, Wang C, Yu H, et al. Structural basis for high-affinity recognition of aflatoxin B1 by a DNA aptamer. Nucleic Acids Res, 2023, 51(14):7666-7674

  • [10]

    Liu H, Gao Y, Mathivanan J, et al. Crystal structures and identification of novel Cd2+-specific DNA aptamer. Nucleic Acids Res, 2023, 51(9): 4625-4636

  • [11]

    Randrianjatovo-Gbalou I, Rosario S, Sismeiro O, et al. Enzymatic synthesis of random sequences of RNA and RNA analogues by DNA polymerase theta mutants for the generation of aptamer libraries. Nucleic Acids Res, 2018, 46(12): 6271-6284

  • [12]

    Chen J, Chen M, Zhu T F. Directed evolution and selection of biostable L-DNA aptamers with a mirror-image DNA polymerase. Nat Biotechnol, 2022, 40(11): 1601-1609

  • [13]

    Yoshikawa A M, Rangel A E, Zheng L, et al. A massively parallel screening platform for converting aptamers into molecular switches. Nat Commun, 2023, 14(1): 2336

  • [14]

    Song P, Fan C. Selecting aptamers with programmed affinities. Nat Chem, 2023, 15(6): 747-748

  • [15]

    Yang K, Mitchell N M, Banerjee S, et al. A functional group-guided approach to aptamers for small molecules. Science, 2023, 380(6648): 942-948

  • [16]

    Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: un amour impossible?. Electrophoresis, 2000, 21(6): 1054-1070

  • [17]

    Mackie E J, Chiquet-Ehrismann R, Pearson C A, et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA, 1987, 84(13): 4621-4625

  • [18]

    Daniels D A, Chen H, Hicke B J, et al. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA, 2003, 100(26): 15416-15421

  • [19]

    Mallikaratchy P, Tang Z, Kwame S, et al. Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt’s lymphoma cells. Mol Cell Proteomics, 2007, 6(12): 2230-2238

  • [20]

    Shangguan D, Cao Z, Meng L, et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res, 2008, 7(5): 2133-2139

  • [21]

    Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA, 2006, 103(32): 11838-11843

  • [22]

    Yang M, Jiang G, Li W, et al. Developing aptamer probes for acute myelogenous leukemia detection and surface protein biomarker discovery. J Hematol Oncol, 2014, 7: 5

  • [23]

    Wu X, Liu H, Han D, et al. Elucidation and structural modeling of CD71 as a molecular target for cell-specific aptamer binding. J Am Chem Soc, 2019, 141(27): 10760-10769

  • [24]

    Wu X, Zhao Z, Bai H, et al. DNA aptamer selected against pancreatic ductal adenocarcinoma for in vivo imaging and clinical tissue recognition. Theranostics, 2015, 5(9): 985-994

  • [25]

    Jia W, Ren C, Wang L, et al. CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX. Oncotarget, 2016, 7(34): 55328-55342

  • [26]

    Van Simaeys D, Turek D, Champanhac C, et al. Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment. Anal Chem, 2014, 86(9): 4521-4527

  • [27]

    Wang L, Bing T, Liu Y, et al. Imaging of neurite network with an anti-L1CAM aptamer generated by neurite-SELEX. J Am Chem Soc, 2018, 140(51): 18066-18073

  • [28]

    Zhou W, Zhao L, Yuan H, et al. A new small cell lung cancer biomarker identified by Cell-SELEX generated aptamers. Exp Cell Res, 2019, 382(2): 111478

  • [29]

    Zhang H, Jin C, Zhang L, et al. CD71-specific aptamer conjugated with monomethyl auristatin E for the treatment of uveal melanoma. ACS Appl Mater Interfaces, 2022, 14(1): 32-40

  • [30]

    Pan Z, Zhu H, Zhang Y, et al. Development of uveal melanoma-specific aptamer for potential biomarker discovery and targeted drug delivery. Anal Chem, 2023, 95(11): 5095-5108

  • [31]

    Mackie E J, Chiquet-Ehrismann R, Pearson C A, et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA, 1987, 84(13): 4621-4625

  • [32]

    Ferreira C S, Papamichael K, Guilbault G, et al. DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal Bioanal Chem, 2008, 390(4): 1039-1050

  • [33]

    Min K, Jo H, Song K, et al. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials, 2011, 32(8): 2124-2132

  • [34]

    Min K, Song K M, Cho M, et al. Simultaneous electrochemical detection of both PSMA(+) and PSMA(-) prostate cancer cells using an RNA/peptide dual-aptamer probe. Chem Commun, 2010, 46(30): 5566-5568

  • [35]

    Qing M, Sun Z, Wang L, et al. CRISPR/Cas12a-regulated homogeneous electrochemical aptasensor for amplified detection of protein. Sens Actuat B Chem, 2021, 348: 130713

  • [36]

    Zhang Z, Pandey R, Li J, et al. High-affinity dimeric aptamers enable the rapid electrochemical detection of wild-type and B.1.1.7 SARS-CoV-2 in unprocessed saliva. Angew Chem Int Ed Engl, 2021, 60(45): 24266-24274

  • [37]

    Curti F, Fortunati S, Knoll W, et al. A folding-based electrochemical aptasensor for the single-step detection of the SARS-CoV-2 Spike protein. ACS Appl Mater Interfaces, 2022, 14(17): 19204-19211

  • [38]

    Jiang Y, Shi M, Liu Y, et al. Aptamer/AuNP biosensor for colorimetric profiling of exosomal proteins. Angew Chem Int Ed Engl, 2017, 56(39): 11916-11920

  • [39]

    Liu C, Zhao J, Tian F, et al. Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers. Nat Biomed Eng, 2019, 3(3): 183-193

  • [40]

    Bai H, Peng R, Wang D, et al. A minireview on multiparameter-activated nanodevices for cancer imaging and therapy. Nanoscale, 2020, 12(42): 21571-21582

  • [41]

    Feng Y, Yang Y, Xiao Y, et al. Multi-parameter inputted logic-gating on aptamer-encoded extracellular vesicles for colorectal cancer diagnosis. Anal Chem, 2023, 95(2): 1132-1139

  • [42]

    Xu Y, Phillips J A, Yan J, et al. Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells. Anal Chem, 2009, 81(17): 7436-7442

  • [43]

    Phillips J A, Xu Y, Xia Z, et al. Enrichment of cancer cells using aptamers immobilized on a microfluidic channel. Anal Chem, 2009, 81(3): 1033-1039

  • [44]

    Barok M, Balazs M, Nagy P, et al. Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett, 2008, 260(1-2): 198-208

  • [45]

    Bamrungsap S, Chen T, Shukoor M I, et al. Pattern recognition of cancer cells using aptamer-conjugated magnetic nanoparticles. ACS Nano, 2012, 6(5): 3974-3981

  • [46]

    Borghei Y S, Hosseini M, Dadmehr M, et al. Visual detection of cancer cells by colorimetric aptasensor based on aggregation of gold nanoparticles induced by DNA hybridization. Anal Chim Acta, 2016, 904: 92-97

  • [47]

    Shahrajabian M, Hormozi-Nezhad M R. Design a new strategy based on nanoparticle-enhanced chemiluminescence sensor array for biothiols discrimination. Sci Rep, 2016, 6: 32160

  • [48]

    Wu Y X, Zhang X B, Zhang D L, et al. Quench-shield ratiometric upconversion luminescence nanoplatform for biosensing. Anal Chem, 2016, 88(3): 1639-1646

  • [49]

    Song Y, Shi Y, Huang M, et al. Bioinspired engineering of a multivalent aptamer‐functionalized nanointerface to enhance the capture and release of circulating tumor cells. Angew Chem Int Ed Engl, 2019, 58(8): 2236-2240

  • [50]

    Li X, Wang T, Xie T, et al. Aptamer-mediated enrichment of rare circulating fetal nucleated red blood cells for noninvasive prenatal diagnosis. Anal Chem, 2023, 95(12): 5419-5427

  • [51]

    Li J, Dong C, Gan H, et al. Nondestructive separation/enrichment and rolling circle amplification-powered sensitive SERS enumeration of circulating tumor cells via aptamer recognition. Biosens Bioelectron, 2023, 231: 115273

  • [52]

    Mankoff D A. A definition of molecular imaging. J Nucl Med, 2007, 48(6): 18N, 21N

  • [53]

    Yan L, Shi H, He X, et al. A versatile activatable fluorescence probing platform for cancer cells in vitro and in vivo based on self-assembled aptamer/carbon nanotube ensembles. Anal Chem, 2014, 86(18): 9271-9277

  • [54]

    Yang Y, Huang J, Yang X, et al. Aptamer-based FRET nanoflares for imaging potassium ions in living cells. Chem Commun, 2016, 52(76): 11386-11389

  • [55]

    Yuan B, Jiang X, Chen Y, et al. Metastatic cancer cell and tissue-specific fluorescence imaging using a new DNA aptamer developed by Cell-SELEX. Talanta, 2017, 170: 56-62

  • [56]

    Ding D, Zhao H, Wei D, et al. The first-in-human whole-body dynamic pharmacokinetics study of aptamer. Research (Wash D C), 2023, 6: 0126

  • [57]

    Anonymous. Pegaptanib sodium (Macugen) for macular degeneration. Med Lett Drug Ther, 2005, 47(1212): 55-56

  • [58]

    Anonymous. New drug treats form of age-related macular degeneration. Macugen inhibits progression of wet AMD and also may restore some vision. Health News, 2005, 11(5): 3-4

  • [59]

    Anonymous. Intravital injection of Macugen. Pharm Unserer Zeit, 2007, 36(6): 470

  • [60]

    Eriksson E S, Joshi L, Billeter M, et al. De novo tertiary structure prediction using RNA123-benchmarking and application to Macugen. J Mol Model, 2014, 20(8): 2389

  • [61]

    Frenkel R E, Mani L, Toler A R, et al. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol, 2007, 143(6): 1034-1035

  • [62]

    Hariprasad S M, Shah G K, Blinder K J. Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol, 2006, 141(1): 200-201

  • [63]

    Katz B, Goldbaum M. Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF). Int Ophthalmol Clin, 2006, 46(4): 141-154

  • [64]

    Jin B, Guo Z, Chen Z, et al. Aptamers in cancer therapy: problems and new breakthroughs. J Mater Chem B, 2023, 11(8): 1609-1627

  • [65]

    Yu Y, Wang L, Ni S, et al. Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation. Nat Commun, 2022, 13(1): 4241

  • [66]

    Gelinas A D, Tan T K, Liu S, et al. Broadly neutralizing aptamers to SARS-CoV-2: a diverse panel of modified DNA antiviral agents. Mol Ther Nucleic Acids, 2023, 31: 370-382

  • [67]

    Chu X, Du X, Yang L, et al. Targeting tumor necrosis factor receptor 1 with selected aptamers for anti-inflammatory activity. ACS Appl Mater Interfaces, 2023, 15(9): 11599-11608

  • [68]

    Patel S S, Lally D R, Hsu J, et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond), 2023. doi:10.1038/s41433-023-02497-w

  • [69]

    Lupold S E, Hicke B J, Lin Y, et al. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res, 2002, 62(14): 4029-4033

  • [70]

    Dhar S, Gu F X, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA, 2008, 105(45): 17356-17361

  • [71]

    Chu T C, Marks J W, Lavery L A, et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res, 2006, 66(12): 5989-5992

  • [72]

    Mcnamara J O, Andrechek E R, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 2006, 24(8): 1005-1015

  • [73]

    Xiao Z, Shangguan D, Cao Z, et al. Cell-specific internalization study of an aptamer from whole cell selection. Chemistry, 2008, 14(6): 1769-1775

  • [74]

    Huang Y F, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem, 2009, 10(5): 862-868

  • [75]

    Shangguan D, Tang Z, Mallikaratchy P, et al. Optimization and modifications of aptamers selected from live cancer cell lines. Chembiochem, 2007, 8(6): 603-606

  • [76]

    Castano A P, Mroz P, Hamblin M R. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer, 2006, 6(7): 535-545

  • [77]

    Taghdisi S M, Abnous K, Mosaffa F, et al. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J Drug Target, 2010, 18(4): 277-281

  • [78]

    He J, Peng T, Peng Y, et al. Molecularly engineering triptolide with aptamers for high specificity and cytotoxicity for triple-negative breast cancer. J Am Chem Soc, 2020, 142(6): 2699-2703

  • [79]

    Deng Z, Yang Q, Peng Y, et al. Polymeric engineering of aptamer-drug conjugates for targeted cancer therapy. Bioconj Chem, 2020, 31(1): 37-42

  • [80]

    Tan Y, Peng Y, Ai L, et al. Aptamer enables consistent maytansine delivery through maintaining receptor homeostasis for HER2 targeted cancer therapy. Bioconj Chem, 2020, 31(7): 1766-1774

  • [81]

    Huang Z, Wang D, Long C Y, et al. Regulating the anticancer efficacy of sgc8-combretastatin A4 conjugates: a case of recognizing the significance of linker chemistry for the design of aptamer-based targeted drug delivery strategies. J Am Chem Soc, 2021, 143(23): 8559-8564

  • [82]

    Wang D, Li S, Zhao Z, et al. Engineering a second-order DNA logic-gated nanorobot to sense and release on live cell membranes for multiplexed diagnosis and synergistic therapy. Angew Chem Int Ed Engl, 2021, 60(29): 15816-15820

  • [83]

    He S, Gao F, Ma J, et al. Aptamer-PROTAC conjugates (APCs) for tumor-specific targeting in breast cancer. Angew Chem Int Ed Engl, 2021, 60(43): 23299-23305

  • [84]

    Xie S, Sun W, Fu T, et al. Aptamer-based targeted delivery of functional nucleic acids. J Am Chem Soc, 2023, 145(14): 7677-7691

  • [85]

    Zhang W, Kohane D S. Keeping nanomedicine on target. Nano Lett, 2021, 21(1): 3-5

  • [86]

    Liu Q, Zou J, Chen Z, et al. Current research trends of nanomedicines. Acta Pharm Sin B, 2023. doi: 10.1016/j.apsb.2023.05.018

  • [87]

    He J, Duan Q, Ran C, et al. Recent progress of aptamer?drug conjugates in cancer therapy. Acta Pharm Sin B, 2023, 13(4): 1358-1370

  • [88]

    Zhang L, Radovic-Moreno A F, Alexis F, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem, 2007, 2(9): 1268-1271

  • [89]

    Wang J, You M, Zhu G, et al. Photosensitizer-gold nanorod composite for targeted multimodal therapy. Small, 2013, 9(21): 3678-3684

  • [90]

    Huang F, You M, Chen T, et al. Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells. Chem Commun, 2014, 50(23): 3103-3105

  • [91]

    Shi H, Ye X, He X, et al. Au@Ag/Au nanoparticles assembled with activatable aptamer probes as smart “nano-doctors” for image-guided cancer thermotherapy. Nanoscale, 2014, 6(15): 8754-8761

  • [92]

    Wang D, Peng R, Peng Y, et al. Hierarchical fabrication of DNA wireframe nanoarchitectures for efficient cancer imaging and targeted therapy. ACS Nano, 2020, 14(12): 17365-17375

  • [93]

    Garcia Melian M F, Moreno M, Cerecetto H, et al. Aptamer-based immunotheranostic strategies. Cancer Biother Radiopharm, 2023, 38(4): 246-255

  • [94]

    周灵丽,叶茂.核酸适配体介导的肿瘤免疫治疗研究进展.生物化学与生物物理进展, 2022, 49(6): 1036-1044Zhou L, Ye M. Prog Biochem Biophys, 2022, 49(6): 1036-1044

  • [95]

    Xiong X, Liu H, Zhao Z, et al. DNA aptamer-mediated cell targeting. Angew Chem Int Ed Engl, 2013, 52(5): 1472-1476

  • [96]

    Herrmann A, Priceman S J, Swiderski P, et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest, 2014, 124(7): 2977-2987

  • [97]

    Prodeus A, Abdul-Wahid A, Fischer N W, et al. Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers. Mol Ther Nucleic Acids, 2015, 4(4): e237

  • [98]

    Chen Z, Zeng Z, Wan Q, et al. Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells. Biomaterials, 2022, 280: 121259

  • [99]

    Thomas B J, Porciani D, Burke D H. Cancer immunomodulation using bispecific aptamers. Mol Ther Nucleic Acids, 2022, 27: 894-915

  • [100]

    Fu J, Yao F, An Y, et al. Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy. Cancer Nanotechnol, 2023, 14(1): 27

  • [101]

    Zhang J, Li W, Qi Y, et al. PD-L1 aptamer-functionalized metal-organic framework nanoparticles for robust photo-immunotherapy against cancer with enhanced safety. Angew Chem Int Ed Engl, 2023, 62(5): e202214750